ACCELERON PHARMA INC (XLRN)
Institutional ownership reported to the SEC as of Q2 2026, across 27 quarters.
1
Reporting holders
$358
Reported value
0.0%
Held as options
+0
Holder change
Options share is the part of reported value carried in derivative lines rather than shares. A high figure means institutions are expressing a view on this security without owning much of it.
Holders
| Filer | Value | Shares | Their book | Held | Change |
|---|---|---|---|---|---|
| HUNTINGTON NATIONAL BANK | $358 | 2 | 0.00% | 15q | HELD |
Quarter by quarter
Coverage begins with the quarter ending 2018-12-31. Earlier filings exist only as occasional late amendments, too sparse to describe a market, so they are not shown.
| Quarter | Holders | Value | Shares | New | Added | Trimmed | Options |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1 | $358 | 2 | 0 | 0 | 0 | 0.0% |
| Q1 2026 | 1 | $358 | 2 | 0 | 0 | 0 | 0.0% |
| Q4 2025 | 1 | $358 | 2 | 0 | 0 | 0 | 0.0% |
| Q3 2025 | 1 | $358 | 2 | 0 | 0 | 0 | 0.0% |
| Q2 2025 | 1 | $358 | 2 | 0 | 0 | 0 | 0.0% |
| Q1 2025 | 1 | $358 | 2 | 0 | 0 | 0 | 0.0% |
| Q4 2024 | 1 | $358 | 2 | 0 | 0 | 0 | 0.0% |
| Q3 2024 | 1 | $358 | 2 | 0 | 0 | 0 | 0.0% |
| Q2 2024 | 1 | $358 | 2 | 0 | 0 | 0 | 0.0% |
| Q1 2024 | 1 | $358 | 2 | 0 | 0 | 0 | 0.0% |
| Q4 2023 | 1 | $358 | 2 | 0 | 0 | 0 | 0.0% |
| Q3 2023 | 1 | $358 | 2 | 0 | 0 | 0 | 0.0% |
| Q2 2023 | 1 | $358 | 2 | 0 | 0 | 0 | 0.0% |
| Q1 2023 | 1 | $358 | 2 | 0 | 0 | 0 | 0.0% |
| Q4 2022 | 1 | $358 | 2 | 1 | 0 | 0 | 0.0% |
| Q3 2021 | 339 | $10.0B | 53,554,901 | 110 | 81 | 100 | 8.0% |
| Q2 2021 | 270 | $6.9B | 54,405,901 | 40 | 84 | 77 | 1.0% |
| Q1 2021 | 258 | $7.4B | 53,915,700 | 31 | 81 | 88 | 1.1% |
| Q4 2020 | 257 | $7.0B | 54,121,165 | 35 | 79 | 83 | 0.9% |
| Q3 2020 | 242 | $6.1B | 54,059,832 | 44 | 94 | 69 | 0.6% |
| Q2 2020 | 247 | $4.7B | 48,505,920 | 57 | 89 | 68 | 2.4% |
| Q1 2020 | 218 | $4.5B | 48,535,842 | 65 | 49 | 76 | 2.7% |
| Q4 2019 | 185 | $2.6B | 49,259,311 | 29 | 59 | 58 | 1.2% |
| Q3 2019 | 175 | $1.9B | 48,367,598 | 15 | 56 | 60 | 0.7% |
| Q2 2019 | 170 | $2.0B | 48,491,311 | 21 | 59 | 45 | 0.9% |
| Q1 2019 | 173 | $2.4B | 49,960,156 | 27 | 71 | 45 | 1.4% |
| Q4 2018 | 162 | $2.0B | 45,010,050 | 2 | 1 | 2 | 1.5% |